Most compounded versions of popular drugs used for weight loss including Wegovy and Zepbound may soon no longer be available after a U.S. judge declined an initial injunction to allow compounding ...

As the contentious debate over compounded weight loss drugs continues, Eli Lilly is stepping out with an ad campaign to further stake its claim as a leader in the obesity market. In the national print ...

Since 2022, four GLP-1 drugs, including those indicated for weight loss, have been on FDA’s drug shortage list due to extraordinarily high patient demand. The shortage has, in turn, resulted in ...

Novo Nordisk on Tuesday asked the Food and Drug Administration to prevent compounding pharmacies from making unapproved and often cheaper versions of its popular weight loss injection Wegovy and ...

Patients have been buying compounded weight loss drugs at lower prices than brand-name medications amid shortages of tirzepatide and semaglutide. (Getty Images) Compounding pharmacies will have to ...

STATE. WE’LL TELL YOU WHY. GOOD EVENING. I’M SHELLY RIBANDO. AND I’M DOUG FERNANDEZ. IT IS A CASE THAT MADE NATIONAL HEADLINES AND THE TRIAL IS OFFICIALLY UNDERWAY NOW HERE IN ALBUQUERQUE. FIVE PEOPLE ...

The Food and Drug Administration (FDA) on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and Wegovy, is no longer in short supply. The FDA's move is bad news for ...

Hims & Hers sells a compounded weight loss medication. A telehealth company that sells a compounded version of medications used for weight loss has found itself at the center of an escalating ...

The war is on between compounding pharmacies making knockoff versions of popular weight loss drugs and pharma giants Novo Nordisk and Eli Lilly, who want to protect their right to sell their patented ...

Weight-loss treatments like semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) have been life changing for many individuals seeking to manage their weight. However, shortages and high ...

The US Food and Drug Administration (FDA) has notified compounding pharmacies that the agency — at least temporarily — won’t take action against them for ...

While glucagon-like peptide-1 (GLP-1) agonists for diabetes and weight loss remain in short supply, some clinicians have turned to compounding pharmacies to fill prescriptions. Yet news reports and ...